Top etanercept Articles in Internal Medicine

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
Canadian Medical Association Journal, 11/24/2009

with adalimumab and etanercept. Adalimumab, anakinra and infliximab were more likely than etanercept to lead to withdrawals related to adverse events. Given the limitations of indirect comparisons, anakinra was less effective than adalimumab and etanercept, and etanercept was safer than adalimumab [more...]

Pretreatment With the Tumor Nerosis Factor-[alpha] Blocker Etanercept Attenuated Ischemia-Reperfusion Renal Injury
Transplantation Proceedings, 11/18/2009

Choi DE et al. – Etanercept improved resistance to renal injury during IR by enhancing the activation of ERK and increasing the Bcl–2/Bax ratio. [more...]

Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study
Journal of Dermatological Treatment, 12/07/2009

Mazzotta A et al. – Etanercept is a safe and effective agent in the long–term management of PsA patients. After 3 years of continuous treatment, symptoms were under control in the ... was a low level of disease activity. [more...]

Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis
Scandinavian Journal of Rheumatology, 11/19/2009

Klimiuk PA et al. – The study shows that, besides a rapid suppression of disease activity, serum sCAM and ... concentrations are downregulated following anti–tumour necrosis factor alpha therapy combined with MTX. Prolonged treatment with etanercept sustained or even more remarkably diminished the sCAM and VEGF serum concentrations. [more...]

Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation
Journal of the European Academy of Dermatology and Venereology, 11/23/2009

Martyn–Simmons CL et al. – Initial data from this open–label prospective evaluation suggests that weekly adalimumab therapy is an effective treatment for patients with severe ... high–dosage etanercept. [more...]

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study
Journal of the European Academy of Dermatology and Venereology, 11/18/2009

Dauden E et al. – At baseline, patients exhibited significant quality–of–life impairment. Both continuous and paused etanercept treatment provided improvements in PRO measures. Either [more...]

Early subcutaneous administration of etanercept (ENBREL) prevents from hyperoxia-induced lung injury
Experimental Lung Research, 11/09/2009

Guthmann F et al. – The authors assume that subcutaneous administration of etanercept might be suitable to prevent acute lung injury and its sequelae induced by hyperoxic ventilation of [more...]

Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis
Modern Rheumatology, 11/25/2009

Tsujimura S et al. – Etanercept is useful for overcoming P-gp-mediated treatment resistance in intractable RA patients who have to discontinue infliximab or are intolerant ... CD69. Incubation of these lymphocytes with dexamethasone in vitro reduced intracellular dexamethasone levels. Two-week etanercept therapy significantly reduced P-gp expression and eliminated such P-gp- and CD69-high-expressing subgroup. The reduction in P-gp resulted in [more...]

Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis
Rheumatology, 11/23/2009

in patients with RA. Methods Large cohort of Caucasian RA patients treated with anti-TNF medications (total, n = 1050; etanercept, n = 455; infliximab, n = 450; and adalimumab, n = 142), sIL-6R A358C polymorphism genotyped using Taqman 5'-allelic discrimination assay [more...]

Repair of erosions occurs almost exclusively in damaged joints without swelling
Annals of Rheumatic Diseases, 11/12/2009

Lukas C et al. – Repair of erosions almost exclusively occurs in joints with improvement or absence of swelling, in patients treated with etanercept. Progression is seen more frequently in joints with persistent swelling, in patients receiving methotrexate monotherapy, primarily if damage is [more...]